FFO
CRBU icon

Fortitude Family Office’s Caribou Biosciences CRBU Stock Holding History

Fortitude Family Office’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83K Buy
964
+318
+49% +$546 ﹤0.01% 1314
2025
Q4 		$1.03K Hold
646
– – ﹤0.01% 1435
2025
Q3 		$1.5K Hold
646
– – ﹤0.01% 1373
2025
Q2 		$814 Buy
+646
New +$635 ﹤0.01% 1602

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fortitude Family Office's CRBU Position: Q1 2026 in Review

Fortitude Family Office increased its Caribou Biosciences (CRBU) stake by 49% in Q1 2026, buying an estimated $546 and bringing the position to 964 shares worth $1.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Fortitude Family Office first reported a position in CRBU in Q2 2025 and has held it in 4 quarters since. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Fortitude Family Office held 964 shares of Caribou Biosciences worth $1.83K as of Q1 2026.
  • Fortitude Family Office bought 318 Caribou Biosciences shares in Q1 2026, an estimated $546.
  • Caribou Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1314 holding.
  • Fortitude Family Office first reported a position in Caribou Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.